Stocktoria
ZIMMER BIOMET HOLDINGS, INC. ZBH
ZIMMER BIOMET HOLDINGS, INC. (ZBH) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.10% (safety: safe). FY2025 revenue was $8.2B at a 8.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.57 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-10 | Canaccord Genuity | Hold (main) |
| 2026-08-07 | Truist Securities | Hold (main) |
| 2026-08-06 | RBC Capital | Outperform (main) |
| 2026-08-06 | Bernstein | Market Perform (main) |
| 2026-08-06 | Stifel | Buy (main) |
| 2026-07-09 | BMO Capital | Market Perform (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.11 |
| Retained earnings / assets | 0.503 |
| EBIT / assets | 0.048 |
| Equity / liabilities | 1.223 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | 5/9 | 3.96 | 24.5 | +7.2% |
| ISRG | INTUITIVE SURGICAL INC | 6/9 | 12.06 | 50.2 | +20.5% |
| EW | Edwards Lifesciences Corp | 6/9 | 9.6 | 48.7 | +11.5% |
| STE | STERIS plc | 9/9 | 4.5 | 26.9 | +8.7% |
| ALGN | ALIGN TECHNOLOGY INC | 6/9 | 4.56 | 31.1 | +0.9% |
| ENOV | Enovis CORP | 4/9 | -1.51 | — | +6.7% |
| MSA | MSA Safety Inc | 6/9 | 5.65 | 23.6 | +3.7% |
About ZIMMER BIOMET HOLDINGS, INC.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
FAQ
Is ZBH financially healthy?
ZIMMER BIOMET HOLDINGS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ZBH pay a dividend, and is it safe?
Yes. ZIMMER BIOMET HOLDINGS, INC. pays a dividend yielding about 1.10% with a 27.0% payout ratio, rated “safe” for safety.
How profitable is ZBH?
In FY2025, ZIMMER BIOMET HOLDINGS, INC. had a net margin of 8.6% and a return on equity of 5.5%.
Is ZBH overvalued or undervalued?
ZIMMER BIOMET HOLDINGS, INC. trades at about 27.6× trailing earnings — near its 10-year norm (10-year range 13.9×–125.2×, median 26.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ZBH?
The average Wall-Street price target for ZIMMER BIOMET HOLDINGS, INC. is $107.57, about 9.9% above the recent price, from 21 analysts (consensus: buy).
Is ZBH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ZIMMER BIOMET HOLDINGS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 24.5×, a dividend yield of 1.10%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.